Apple News Facebook Twitter 新浪微博 Instagram YouTube Wednesday, Feb 20, 2019

China greenlights more cancer medicines in 2018

(咪牌百家乐)    08:49, February 20, 2019

BEIJING, Feb. 19 (Xinhua) -- China's National Medical Products Administration (NMPA) approved 18 new cancer medicines in 2018, up 157 percent on 2017, said an NMPA official Tuesday.

Cancer medicines accounted for 37.5 percent of the total new medicines approved in 2018, "a notable increase over previous years," said Wang Ping, chief of the division of medicine registration under the NMPA, at a press conference.

"It takes 12 months on average for a new anti-cancer medicine to be approved by the NMPA, down from 24 months before 2018," Wang said.

Last year the Chinese government adopted a series of measures to speed up the approval of imported and domestically-developed cancer medicines.

According to Wang, the government exempted imported medicines from quarantine at border ports so they could reach hospitals and pharmacies as quickly as possible. The approving procedure for imported medicines to enter the Chinese market as well as that for domestic pharmaceutical firms to conduct clinical tests were also simplified.

The NMPA and National Health Commission (NHC) listed 48 types of imported medicines that were much needed in China, including those for rare and deadly diseases. The review period of imported medicines for rare diseases is three months, while for the rest it is six months.

"The country has tried to develop a favorable policy environment for innovation in medicines so that the latest medical research findings could benefit Chinese patients as soon as possible," Wang said.

This year the NMPA will work with the NHC to develop the second list of much needed imported medicines that are qualified for fast-track review, he said.

The NMPA will also try to speed up the review procedure for imported and domestic cancer medicines and tighten up monitoring of adverse reactions, he added.

(For the latest China news, Please follow People's Daily on Twitter and Facebook)(Web editor: Sheng Chuyi, Liang Jun)

Add your comment

Related reading

We Recommend

Most Read

Key Words

网站地图 澳门金沙娱乐场 申博游戏 申博太阳城登入 申博娱乐手机登入
申博在线代理开户 申博官网 申博亚洲太阳城娱乐 申博游戏登录
申博娱乐 申博网址 百家乐登入网址 申博手机版
澳门大三巴赌场 申博138官网 申博游戏手机下载 申博官网登录
太阳城app下载 ag国际馆 申博现金网 申博游戏